Decisions 14th October 2014


  

At the meeting on the 14th October 2014 the following decisions / changes to the formulary were agreed

 

New Drug Requests

Approved

Ubidecarenone (Co-enzyme Q10) (TLS Red)

  • Approved for patients with mitochondrial disease who have skeletal myopathy with symptoms of pain and fatigue under the care of Dr Merrison (NBT).

DuoResp (Budesonide and formoterol) Spiromax inhaler (TLS Green)

  • Approved for COPD maintenance and asthma.

Paliperidone palmitate (TLS Red)

  • Approved for schizophrenia.  

 

Shared Care Protocols/TLS Change in Status 

Acamprosate

  • Revised/updated SCP accepted.   

Valproate semisodium (Depakote)

  • Revised/updated SCP accepted. 

Apomorphine

  • An application to change the TLS Status to amber was considered but rejected.  Prescribing responsibbility should remain with the specialist.   

Denosumab

  • It was noted that the MHRA had issued advice leading to a change in the requirements for monitoring whilst patients are being treated with denosumab.  We are currently in discussion with the specilaists to update the current SCP for the treatment of osteoporosis. 

 

Last updated by: on 22-01-2015 12:00